Procurement Stickiness Favors Incumbents Over Pathos

The real advantage sits with whoever already controls the buying workflow inside a pharma sponsor. IQVIA and Veeva are hard to dislodge because sponsors already use them to design trials, manage regulated documents, run quality and safety workflows, and coordinate CRO work. That means an AI feature can be sold as an add on to an existing master relationship, while Pathos still has to win a larger platform switch.

• IQVIA is not just software, it also sells trial operations and recruitment support. Its clinical R&D products now market AI for site selection, patient recruitment, planning, and trial execution, so a sponsor can buy new AI capabilities from the same vendor already running large parts of the study.
  2 iqvia 3 iqvia
• Veeva owns daily regulated work inside many life sciences teams. Its Vault products sit where teams store documents, route approvals, manage submissions, and track compliance, and Veeva has rolled out AI agents across clinical, regulatory, safety, quality, medical, and commercial applications, making AI a bundle inside the existing system of record.
  4 veeva 5 sacra
• Caris has a different kind of stickiness. Its molecular profiling lab produces fresh tumor data, then uses that data for trial matching, patient identification, and biopharma services. Because the testing, database, and navigator workflow are already tied together, sponsors can buy trial enablement from a vendor that is already generating the underlying patient data.
  6 carislifesciences 7 carislifesciences 8 carislifesciences 9 carislifesciences

Going forward, Pathos has the best opening where sponsors want a new prediction layer that spans data silos rather than another point feature. But incumbents will keep getting stronger as they attach AI to the tools buyers already trust, and Caris will keep compounding value as every new test feeds the trial matching and data licensing engine.